Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes
Eric Owusu Obeng1, Isabella Rusciano1, Maria Vittoria Marvi1
1Cellular Signalling Laboratory, Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Via Irnerio 48, 40126 Bologna, Italy.
Abstract:
Phosphoinositides (PI) form just a minor portion of the total phospholipid content in cells but are significantly involved in cancer development and progression. In several cancer types, phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] and phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] play significant roles in regulating survival, proliferation, invasion, and growth of cancer cells. Phosphoinositide-specific phospholipase C (PLC) catalyze the generation of the essential second messengers diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (InsP3) by hydrolyzing PtdIns(4,5)P2. DAG and InsP3 regulate Protein Kinase C (PKC) activation and the release of calcium ions (Ca2+) into the cytosol, respectively. This event leads to the control of several important biological processes implicated in cancer. PLCs have been extensively studied in cancer but their regulatory roles in the oncogenic process are not fully understood. This review aims to provide up-to-date knowledge on the involvement of PLCs in cancer. We focus specifically on PLCβ, PLCγ, PLCδ, and PLCε isoforms due to the numerous evidence of their involvement in various cancer types.
Insights
Phosphoinositide-specific phospholipase C (PLC) enzymes are crucial in cancer, regulating cell survival and proliferation. This review details PLC involvement in various cancer types, focusing on PLCβ, PLCγ, PLCδ, and PLCε isoforms.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Phosphoinositides (PI) are minor cell components but critical in cancer progression.
- Specific PIs like PtdIns(3,4,5)P3 and PtdIns(4,5)P2 regulate key cancer cell behaviors.
- Phosphoinositide-specific phospholipase C (PLC) enzymes hydrolyze PtdIns(4,5)P2, generating second messengers.
Purpose of the Study:
- To review the current understanding of phosphoinositide-specific phospholipase C (PLC) involvement in cancer.
- To highlight the roles of PLCβ, PLCγ, PLCδ, and PLCε isoforms in oncogenesis.
Main Methods:
- Literature review of studies on PLC isoforms and their functions in cancer.
- Analysis of evidence linking PLC activity to cancer cell survival, proliferation, invasion, and growth.
Main Results:
- Diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (InsP3) produced by PLC regulate Protein Kinase C (PKC) and calcium release.
- These signaling events are implicated in numerous biological processes vital to cancer.
- Specific PLC isoforms (PLCβ, PLCγ, PLCδ, PLCε) show significant involvement across various cancer types.
Conclusions:
- Phosphoinositide-specific phospholipase C enzymes play multifaceted roles in cancer development and progression.
- Further research is needed to fully elucidate the regulatory mechanisms of PLCs in oncogenic processes.
More Related Videos
10:52Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation
Published on: January 6, 2016
08:07Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
Published on: July 26, 2019
Related Concept Videos
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
IP3/DAG Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Amplifying Signals via Second Messengers
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
